Reappraisal of biochemical hepatitis C activity in hemodialysis patients

Journal of Clinical Gastroenterology

Volumn 30, Issue 2, 2000, Pages 187-194

  Yuki, Nobukazu ^a   Ishida, Hisashi ^b   Inoue, Takashi ^c   Tabata, Tsutomu ^c   Matsushita, Yoshiki ^c   Kishimoto, Hiroshi ^c   Kato, Michio ^a   Masuzawa, Manabu ^a   Sasaki, Yutaka ^b   Hayashi, Norio ^b   Hori, Masatsugu ^b  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c Inoue Hospital   (Japan)

Author keywords

Amino transferase; GB virus C; Hemodialysis; Hepatitis C; Hepatitis G virus

Indexed keywords

ALANINE AMINOTRANSFERASE; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS G VIRUS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERINFECTION; VIREMIA;

ALANINE TRANSAMINASE; CASE-CONTROL STUDIES; ENZYME TESTS; FEMALE; FLAVIVIRIDAE; FOLLOW-UP STUDIES; HEPATITIS C; HEPATITIS, VIRAL, HUMAN; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREVALENCE; REFERENCE VALUES; RENAL DIALYSIS; TIME FACTORS;

EID: 0034018006     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200003000-00012     Document Type: Article

References (17)

1. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
2. Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-500.
3. Mathurin P, Moussalli J, Cadranel J-F, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-72.
4. Chan TM, Lok ASF, Cheng IKP, Chan RT. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. Hepatology 1993;17:5-8.
5. Simon N, Couroucé A-M, Lemarrec N, Trépo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int 1994;46:504-11.
6. Wolf PL, Williams D, Coplon N, Coulson AS. Low aspartate transaminase activity in serum of patients undergoing chronic hemodialysis. Clin Chem 1972;18:567-8.
7. Warnock LG, Stone WJ, Wagner C. Decreased aspartate aminotransferase ("SGOT") activity in serum of uremic patients. Clin Chem 1974;20:1213-6.
8. Cohen GA, Goffinet JA, Donabedian RK, Conn HO. Observations on decreased serum glutamic oxaloacetic transaminase (SGOT) activity in azotemic patients. Ann Intern Med 1976;84:275-80.
9. Yasuda K, Okuda K, Endo N, et al. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Gastroenterology 1995;109:1295-300.
10. Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104:877-83.
11. Takamizawa A, Mori C, Fuke I, et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 1991;65: 1105-13.
12. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19:1347-53.
13. Leary TP, Muerhoff AS, Simons JN, et al. Consensus oligonucleotide primers for the detection of GB virus C in human cryptogenic hepatitis. J Virol Methods 1996;56:119-21.
14. Lou S, Qiu X, Tegtmeier G, et al. Immunoassays to study prevalence of antibody against GB virus C in blood donors. J Virol Methods 1997;68:45-55.
15. London WT, DiFiglia M, Sutnick Al, Blumberg BS. An epidemic of hepatitis in a chronic-hemodialysis unit. N Engl J Med 1969;281:571-8.
16. Poynard T, Bedossa P, Opolon P, the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
17. Pol S, Thiers V, Carnot F, et al. Efficacy and tolerance of α-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995;47: 1412-8.